FDA grants fast review to BMS’ first-line lung cancer comboBristol-Myers Squibb has finally made its bid for a slice of the lucrative first-line lung non-small cell lung Share XFDA grants fast review to BMS’ first-line lung cancer combohttps://pharmaphorum.com/news/fda-grants-fast-review-to-bms-first-line-lung-cancer-combo/
Merck & Co’s Keytruda produces mixed results in SCLCMerck & Co’s Keytruda immunotherapy has produced mixed results in a phase 3 trial testing it in first-line Share XMerck & Co’s Keytruda produces mixed results in SCLChttps://pharmaphorum.com/news/merck-cos-keytruda-produces-mixed-results-in-sclc/
Merck & Co joins KRAS gold rush with Taiho and Astex collaborationUS-based Merck & Co has forged an R&D tie-up with Taiho and Astex Pharmaceuticals, focused on developing small Share XMerck & Co joins KRAS gold rush with Taiho and Astex collaborationhttps://pharmaphorum.com/news/merck-co-joins-kras-gold-rush-with-taiho-and-astex-collaboration/
AZ, Merck add pancreatic cancer to Lynparza’s growing use listAstraZeneca and Merck & Co have cemented their lead in the PARP inhibitor class with FDA approval for Share XAZ, Merck add pancreatic cancer to Lynparza’s growing use listhttps://pharmaphorum.com/news/az-merck-add-pancreatic-cancer-to-lynparzas-growing-use-list/
FDA clears Eisai’s insomnia drug DayvigoThe FDA’s traditional last-minute flurry of approvals as the year heads to a close included Eisai’s Dayvigo, a Share XFDA clears Eisai’s insomnia drug Dayvigohttps://pharmaphorum.com/news/fda-clears-eisais-insomnia-drug-dayvigo/
2019: the year of the pharma mega-merger2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year Share X2019: the year of the pharma mega-mergerhttps://pharmaphorum.com/views-and-analysis/2019-the-year-of-the-pharma-mega-merger/
Merck claims first-ever FDA approval for an Ebola vaccineMerck & Co’s Ebola vaccine Ervebo has been cleared for marketing in the US, just weeks after getting Share XMerck claims first-ever FDA approval for an Ebola vaccinehttps://pharmaphorum.com/news/merck-claims-first-ever-fda-approval-for-an-ebola-vaccine/
AZ’s Lynparza inches towards ‘game changer’ okay in pancreatic cancerAstraZeneca and Merck & Co are closer to a new use for their PARP inhibitor Lynparza in pancreatic Share XAZ’s Lynparza inches towards ‘game changer’ okay in pancreatic cancerhttps://pharmaphorum.com/news/azs-lynparza-inches-towards-game-changer-okay-in-pancreatic-cancer/
Merck’s last-resort antibiotic Recarbrio nears EU approvalMerck & Co/MSD’s three-drug antibiotic Recarbrio has been recommended for approval in Europe for Gram-negative infections, but should Share XMerck’s last-resort antibiotic Recarbrio nears EU approvalhttps://pharmaphorum.com/news/mercks-last-resort-antibiotic-recarbrio-nears-eu-approval/
